Exagen Other Current Assets from 2010 to 2025

XGN Stock  USD 4.25  0.39  10.10%   
Exagen Other Current Assets yearly trend continues to be very stable with very little volatility. Other Current Assets are likely to grow to about 6.9 M this year. Other Current Assets is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. View All Fundamentals
 
Other Current Assets  
First Reported
2013-12-31
Previous Quarter
4.1 M
Current Value
6.6 M
Quarterly Volatility
1.5 M
 
Yuan Drop
 
Covid
Check Exagen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exagen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 2.8 M or Total Revenue of 34.6 M, as well as many indicators such as Price To Sales Ratio of 1.33, Dividend Yield of 0.0169 or PTB Ratio of 8.21. Exagen financial statements analysis is a perfect complement when working with Exagen Valuation or Volatility modules.
  
Check out the analysis of Exagen Correlation against competitors.

Latest Exagen's Other Current Assets Growth Pattern

Below is the plot of the Other Current Assets of Exagen Inc over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. Exagen's Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Exagen's overall financial position and show how it may be relating to other accounts over time.
Other Current Assets10 Years Trend
Slightly volatile
   Other Current Assets   
       Timeline  

Exagen Other Current Assets Regression Statistics

Arithmetic Mean2,031,762
Geometric Mean980,310
Coefficient Of Variation109.02
Mean Deviation1,726,453
Median1,174,000
Standard Deviation2,214,965
Sample Variance4.9T
Range6.8M
R-Value0.84
Mean Square Error1.6T
R-Squared0.70
Significance0.00005
Slope390,081
Total Sum of Squares73.6T

Exagen Other Current Assets History

20256.9 M
20246.6 M
20231.9 M
20222.3 M
20212.5 M
20204.2 M
20193.5 M

About Exagen Financial Statements

Exagen investors utilize fundamental indicators, such as Other Current Assets, to predict how Exagen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Current Assets6.6 M6.9 M

Pair Trading with Exagen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:
Check out the analysis of Exagen Correlation against competitors.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.91)
Revenue Per Share
3.057
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.17)
Return On Equity
(0.94)
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.